Abstract
Bullous pemphigoid is the most common autoimmune blistering disease induced by autoantibodies against basement membrane anchoring proteins (anti‐BP‐180 and anti‐BP‐230). The disease generally appears after the age of 70 and is associated with a 23.5% 1‐year mortality, especially in diabetics, or in the presence of ischemic heart disease and high anti‐BP‐180. Treatment starts with topical steroids but some patients may require oral steroids and systemic immunosuppression. We, hereby, discuss a diabetic patient on chronic hemodialysis, with severely relapsed bullous pemphigoid under biotherapy with omalizumab, who was successfully treated with five sessions of double filtration plasmapheresis, thus avoiding the need for systemic steroids.